ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Using Cu-Based Metal-Organic Framework as a Comprehensive and Powerful Antioxidant Nanozyme for Efficient Osteoarthritis Treatment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 109 citations in OpenAlex.
- Electron-rearranged CuMg@ZIF nanoplatform for pH-Responsive sequential therapy: From infection eradication to neuroangiogenesis in diabetic wounds.Bioactive materials · 2027Article
- Nanozyme-based therapeutic strategies for traumatic brain injury.International journal of pharmaceutics: X · 2026Review
- Redox-immune modulating gadolinium vanadate based nanozymes for osteoarthritis therapy.Materials today. Bio · 2026Article
- Single-atom nanozymes in nanomedicine: catalytic precision, mechanistic insights, and translational opportunities.Chemical science · 2026Review
- A Dual-Responsive Claringbullite-Like Nanozyme for Inhibition of Non-Small Cell Lung Cancer Progression.Small methods · 2026Article
- Augmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy.Journal of nanobiotechnology · 2026Review
- Metal-Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical Applications.Nano-micro letters · 2026Review
- Asymmetric Cu─N─Ru Bridgedsite Nanozyme-Loaded Injectable Thermogel Boosts Cuproptosis-Like Death for Multidrug-Resistant Urinary Tract Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cu-based metal-organic frameworks: synthesis, biomedical applications, and beyond.Discover nano · 2026Review
- Clusterzymes-driven therapy: ultrasmall CuJournal of nanobiotechnology · 2026Article
- Multimodal modulation of metal-based nanomaterials in osteoarthritis immunotherapy: current landscape and future paradigms.Frontiers in immunology · 2026Review
- All Nanozyme-Based Cascade Reactions for Biomedical Applications: from Self-Cascading Nanozyme to Immobilized Cascade Nanozyme.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Constructing Dual-Atomic Fe─Fe Sites Nanozyme for Targeted Osteoarthritis Therapy through Mitigating Oxidative Stress and Cartilage Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bimetallic Copper-Manganese Zeolitic Imidazolate Framework Nanozyme Scavenges Reactive Oxygen Species to Alleviate Osteoarthritis via Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Axis and Autophagic Flux Restoration.Biomaterials research · 2026Article
- Nanozyme-Mediated Joint Homeostasis Restoration: Emerging Strategies for Arthritis Therapy.International journal of nanomedicine · 2026Review
- Stimuli-responsive hydrogels based on cascade reactions: a novel strategy to promote the efficient repair of diabetic wounds.Theranostics · 2026Review
- Antioxidant Nanozymes: From Rational Design to Biomedical Applications.Research (Washington, D.C.) · 2026Review
- Metal-Based Categorization of Recent Metal Organic Frameworks with Application in Bone Disease Treatment.ACS biomaterials science & engineering · 2025Review
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Enhancement of the Antioxidant Activity ofMolecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
Developing nanozymes with effective reactive oxygen species (ROS) scavenging ability is a promising approach for osteoarthritis (OA) treatment. Nonetheless, numerous nanozymes lie in their relatively low antioxidant activity. In certain circumstances, some of these nanozymes may even instigate ROS production to cause side effects. To address these challenges, a copper-based metal-organic framework (Cu MOF) nanozyme is designed and applied for OA treatment. Cu MOF exhibits comprehensive and powerful activities (i.e., SOD-like, CAT-like, and •OH scavenging activities) while negligible pro-oxidant activities (POD- and OXD-like activities). Collectively, Cu MOF nanozyme is more effective at scavenging various types of ROS than other Cu-based antioxidants, such as commercial CuO and Cu single-atom nanozyme. Density functional theory calculations also confirm the origin of its outstanding enzyme-like activities. In vitro and in vivo results demonstrate that Cu MOF nanozyme exhibits an excellent ability to decrease intracellular ROS levels and relieve hypoxic microenvironment of synovial macrophages. As a result, Cu MOF nanozyme can modulate the polarization of macrophages from pro-inflammatory M1 to anti-inflammatory M2 subtype, and inhibit the degradation of cartilage matrix for efficient OA treatment. The excellent biocompatibility and protective properties of Cu MOF nanozyme make it a valuable asset in treating ROS-related ailments beyond OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.